ATHENA–MONO (GOG-3020/ENGOT-ov45): A randomized, double-blind, phase 3 trial evaluating rucaparib monotherapy versus placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer

June 22, 2022 | Bradley Monk, MD, FACS, FACOG

Share on:
View More
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    View More
    Current Time 0:00
    Duration 0:00
    Loaded: 0%
    Stream Type LIVE
    Remaining Time 0:00
     
    1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Bradley Monk, MD, FACS, FACOG, presents slides from the American Society of Clinical Oncology 2022 (ASCO) conference and discusses the use of rucaparib as maintenance treatment for ovarian cancer.